Transarterial	B:C3539919
chemoembolization	I:C3539919
of	O
hepatocellular	O
carcinoma	I:C2239176
with	O
segmental	O
portal	I:C0032718
vein	I:C0032718
tumour	O
thrombus	I:C3163918
.	O

Transarterial	O
chemoembolization	I:C3539919
of	O
hepatocellular	B:C2239176
carcinoma	I:C2239176
with	O
segmental	O
portal	I:C0032718
vein	I:C0032718
tumour	O
thrombus	I:C3163918
.	O

Transarterial	O
chemoembolization	I:C3539919
of	O
hepatocellular	O
carcinoma	I:C2239176
with	O
segmental	B:C0032718
portal	I:C0032718
vein	I:C0032718
tumour	O
thrombus	I:C3163918
.	O

Transarterial	O
chemoembolization	I:C3539919
of	O
hepatocellular	O
carcinoma	I:C2239176
with	O
segmental	O
portal	I:C0032718
vein	I:C0032718
tumour	B:C3163918
thrombus	I:C3163918
.	O

To	O
evaluate	O
the	O
clinical	O
outcome	O
and	O
safety	O
of	O
transarterial	B:C3539919
chemoembolization	I:C3539919
(	O
transarterial	O
chemoembolization	I:C3539919
)	O
for	O
hepatocellular	O
carcinoma	I:C2239176
(	O
hepatocellular	O
carcinoma	I:C2239176
)	O
with	O
segmental	O
or	O
subsegmental	O
portal	I:C0032718
vein	I:C0032718
tumour	O
thrombus	I:C3163918
(	O
subsegmental	O
portal	I:C3163918
vein	I:C3163918
tumour	I:C3163918
thrombus	I:C3163918
)	O
in	O
patients	O
with	O
preserved	O
hepatic	O
function	I:C0232741
,	O
and	O
to	O
address	O
the	O
efficacy	O
of	O
additional	O
chemoinfusion	O
after	O
transarterial	O
chemoembolization	I:C3539919
(	O
transarterial	O
chemoembolization	I:C3539919
+	O
CI	O
)	O
.	O

To	O
evaluate	O
the	O
clinical	O
outcome	O
and	O
safety	O
of	O
transarterial	O
chemoembolization	I:C3539919
(	O
transarterial	B:C3539919
chemoembolization	I:C3539919
)	O
for	O
hepatocellular	O
carcinoma	I:C2239176
(	O
hepatocellular	O
carcinoma	I:C2239176
)	O
with	O
segmental	O
or	O
subsegmental	O
portal	I:C0032718
vein	I:C0032718
tumour	O
thrombus	I:C3163918
(	O
subsegmental	O
portal	I:C3163918
vein	I:C3163918
tumour	I:C3163918
thrombus	I:C3163918
)	O
in	O
patients	O
with	O
preserved	O
hepatic	O
function	I:C0232741
,	O
and	O
to	O
address	O
the	O
efficacy	O
of	O
additional	O
chemoinfusion	O
after	O
transarterial	O
chemoembolization	I:C3539919
(	O
transarterial	O
chemoembolization	I:C3539919
+	O
CI	O
)	O
.	O

To	O
evaluate	O
the	O
clinical	O
outcome	O
and	O
safety	O
of	O
transarterial	O
chemoembolization	I:C3539919
(	O
transarterial	O
chemoembolization	I:C3539919
)	O
for	O
hepatocellular	B:C2239176
carcinoma	I:C2239176
(	O
hepatocellular	O
carcinoma	I:C2239176
)	O
with	O
segmental	O
or	O
subsegmental	O
portal	I:C0032718
vein	I:C0032718
tumour	O
thrombus	I:C3163918
(	O
subsegmental	O
portal	I:C3163918
vein	I:C3163918
tumour	I:C3163918
thrombus	I:C3163918
)	O
in	O
patients	O
with	O
preserved	O
hepatic	O
function	I:C0232741
,	O
and	O
to	O
address	O
the	O
efficacy	O
of	O
additional	O
chemoinfusion	O
after	O
transarterial	O
chemoembolization	I:C3539919
(	O
transarterial	O
chemoembolization	I:C3539919
+	O
CI	O
)	O
.	O

To	O
evaluate	O
the	O
clinical	O
outcome	O
and	O
safety	O
of	O
transarterial	O
chemoembolization	I:C3539919
(	O
transarterial	O
chemoembolization	I:C3539919
)	O
for	O
hepatocellular	O
carcinoma	I:C2239176
(	O
hepatocellular	B:C2239176
carcinoma	I:C2239176
)	O
with	O
segmental	O
or	O
subsegmental	O
portal	I:C0032718
vein	I:C0032718
tumour	O
thrombus	I:C3163918
(	O
subsegmental	O
portal	I:C3163918
vein	I:C3163918
tumour	I:C3163918
thrombus	I:C3163918
)	O
in	O
patients	O
with	O
preserved	O
hepatic	O
function	I:C0232741
,	O
and	O
to	O
address	O
the	O
efficacy	O
of	O
additional	O
chemoinfusion	O
after	O
transarterial	O
chemoembolization	I:C3539919
(	O
transarterial	O
chemoembolization	I:C3539919
+	O
CI	O
)	O
.	O

To	O
evaluate	O
the	O
clinical	O
outcome	O
and	O
safety	O
of	O
transarterial	O
chemoembolization	I:C3539919
(	O
transarterial	O
chemoembolization	I:C3539919
)	O
for	O
hepatocellular	O
carcinoma	I:C2239176
(	O
hepatocellular	O
carcinoma	I:C2239176
)	O
with	O
segmental	B:C0205122
or	O
subsegmental	O
portal	I:C0032718
vein	I:C0032718
tumour	O
thrombus	I:C3163918
(	O
subsegmental	O
portal	I:C3163918
vein	I:C3163918
tumour	I:C3163918
thrombus	I:C3163918
)	O
in	O
patients	O
with	O
preserved	O
hepatic	O
function	I:C0232741
,	O
and	O
to	O
address	O
the	O
efficacy	O
of	O
additional	O
chemoinfusion	O
after	O
transarterial	O
chemoembolization	I:C3539919
(	O
transarterial	O
chemoembolization	I:C3539919
+	O
CI	O
)	O
.	O

To	O
evaluate	O
the	O
clinical	O
outcome	O
and	O
safety	O
of	O
transarterial	O
chemoembolization	I:C3539919
(	O
transarterial	O
chemoembolization	I:C3539919
)	O
for	O
hepatocellular	O
carcinoma	I:C2239176
(	O
hepatocellular	O
carcinoma	I:C2239176
)	O
with	O
segmental	O
or	O
subsegmental	B:C0032718
portal	I:C0032718
vein	I:C0032718
tumour	O
thrombus	I:C3163918
(	O
subsegmental	O
portal	I:C3163918
vein	I:C3163918
tumour	I:C3163918
thrombus	I:C3163918
)	O
in	O
patients	O
with	O
preserved	O
hepatic	O
function	I:C0232741
,	O
and	O
to	O
address	O
the	O
efficacy	O
of	O
additional	O
chemoinfusion	O
after	O
transarterial	O
chemoembolization	I:C3539919
(	O
transarterial	O
chemoembolization	I:C3539919
+	O
CI	O
)	O
.	O

To	O
evaluate	O
the	O
clinical	O
outcome	O
and	O
safety	O
of	O
transarterial	O
chemoembolization	I:C3539919
(	O
transarterial	O
chemoembolization	I:C3539919
)	O
for	O
hepatocellular	O
carcinoma	I:C2239176
(	O
hepatocellular	O
carcinoma	I:C2239176
)	O
with	O
segmental	O
or	O
subsegmental	O
portal	I:C0032718
vein	I:C0032718
tumour	B:C3163918
thrombus	I:C3163918
(	O
subsegmental	O
portal	I:C3163918
vein	I:C3163918
tumour	I:C3163918
thrombus	I:C3163918
)	O
in	O
patients	O
with	O
preserved	O
hepatic	O
function	I:C0232741
,	O
and	O
to	O
address	O
the	O
efficacy	O
of	O
additional	O
chemoinfusion	O
after	O
transarterial	O
chemoembolization	I:C3539919
(	O
transarterial	O
chemoembolization	I:C3539919
+	O
CI	O
)	O
.	O

To	O
evaluate	O
the	O
clinical	O
outcome	O
and	O
safety	O
of	O
transarterial	O
chemoembolization	I:C3539919
(	O
transarterial	O
chemoembolization	I:C3539919
)	O
for	O
hepatocellular	O
carcinoma	I:C2239176
(	O
hepatocellular	O
carcinoma	I:C2239176
)	O
with	O
segmental	O
or	O
subsegmental	O
portal	I:C0032718
vein	I:C0032718
tumour	O
thrombus	I:C3163918
(	O
subsegmental	B:C3163918
portal	I:C3163918
vein	I:C3163918
tumour	I:C3163918
thrombus	I:C3163918
)	O
in	O
patients	O
with	O
preserved	O
hepatic	O
function	I:C0232741
,	O
and	O
to	O
address	O
the	O
efficacy	O
of	O
additional	O
chemoinfusion	O
after	O
transarterial	O
chemoembolization	I:C3539919
(	O
transarterial	O
chemoembolization	I:C3539919
+	O
CI	O
)	O
.	O

To	O
evaluate	O
the	O
clinical	O
outcome	O
and	O
safety	O
of	O
transarterial	O
chemoembolization	I:C3539919
(	O
transarterial	O
chemoembolization	I:C3539919
)	O
for	O
hepatocellular	O
carcinoma	I:C2239176
(	O
hepatocellular	O
carcinoma	I:C2239176
)	O
with	O
segmental	O
or	O
subsegmental	O
portal	I:C0032718
vein	I:C0032718
tumour	O
thrombus	I:C3163918
(	O
subsegmental	O
portal	I:C3163918
vein	I:C3163918
tumour	I:C3163918
thrombus	I:C3163918
)	O
in	O
patients	O
with	O
preserved	O
hepatic	B:C0232741
function	I:C0232741
,	O
and	O
to	O
address	O
the	O
efficacy	O
of	O
additional	O
chemoinfusion	O
after	O
transarterial	O
chemoembolization	I:C3539919
(	O
transarterial	O
chemoembolization	I:C3539919
+	O
CI	O
)	O
.	O

To	O
evaluate	O
the	O
clinical	O
outcome	O
and	O
safety	O
of	O
transarterial	O
chemoembolization	I:C3539919
(	O
transarterial	O
chemoembolization	I:C3539919
)	O
for	O
hepatocellular	O
carcinoma	I:C2239176
(	O
hepatocellular	O
carcinoma	I:C2239176
)	O
with	O
segmental	O
or	O
subsegmental	O
portal	I:C0032718
vein	I:C0032718
tumour	O
thrombus	I:C3163918
(	O
subsegmental	O
portal	I:C3163918
vein	I:C3163918
tumour	I:C3163918
thrombus	I:C3163918
)	O
in	O
patients	O
with	O
preserved	O
hepatic	O
function	I:C0232741
,	O
and	O
to	O
address	O
the	O
efficacy	O
of	O
additional	O
chemoinfusion	B:C0574032
after	O
transarterial	O
chemoembolization	I:C3539919
(	O
transarterial	O
chemoembolization	I:C3539919
+	O
CI	O
)	O
.	O

To	O
evaluate	O
the	O
clinical	O
outcome	O
and	O
safety	O
of	O
transarterial	O
chemoembolization	I:C3539919
(	O
transarterial	O
chemoembolization	I:C3539919
)	O
for	O
hepatocellular	O
carcinoma	I:C2239176
(	O
hepatocellular	O
carcinoma	I:C2239176
)	O
with	O
segmental	O
or	O
subsegmental	O
portal	I:C0032718
vein	I:C0032718
tumour	O
thrombus	I:C3163918
(	O
subsegmental	O
portal	I:C3163918
vein	I:C3163918
tumour	I:C3163918
thrombus	I:C3163918
)	O
in	O
patients	O
with	O
preserved	O
hepatic	O
function	I:C0232741
,	O
and	O
to	O
address	O
the	O
efficacy	O
of	O
additional	O
chemoinfusion	O
after	O
transarterial	B:C3539919
chemoembolization	I:C3539919
(	O
transarterial	O
chemoembolization	I:C3539919
+	O
CI	O
)	O
.	O

To	O
evaluate	O
the	O
clinical	O
outcome	O
and	O
safety	O
of	O
transarterial	O
chemoembolization	I:C3539919
(	O
transarterial	O
chemoembolization	I:C3539919
)	O
for	O
hepatocellular	O
carcinoma	I:C2239176
(	O
hepatocellular	O
carcinoma	I:C2239176
)	O
with	O
segmental	O
or	O
subsegmental	O
portal	I:C0032718
vein	I:C0032718
tumour	O
thrombus	I:C3163918
(	O
subsegmental	O
portal	I:C3163918
vein	I:C3163918
tumour	I:C3163918
thrombus	I:C3163918
)	O
in	O
patients	O
with	O
preserved	O
hepatic	O
function	I:C0232741
,	O
and	O
to	O
address	O
the	O
efficacy	O
of	O
additional	O
chemoinfusion	O
after	O
transarterial	O
chemoembolization	I:C3539919
(	O
transarterial	B:C3539919
chemoembolization	I:C3539919
+	O
CI	O
)	O
.	O

To	O
evaluate	O
the	O
clinical	O
outcome	O
and	O
safety	O
of	O
transarterial	O
chemoembolization	I:C3539919
(	O
transarterial	O
chemoembolization	I:C3539919
)	O
for	O
hepatocellular	O
carcinoma	I:C2239176
(	O
hepatocellular	O
carcinoma	I:C2239176
)	O
with	O
segmental	O
or	O
subsegmental	O
portal	I:C0032718
vein	I:C0032718
tumour	O
thrombus	I:C3163918
(	O
subsegmental	O
portal	I:C3163918
vein	I:C3163918
tumour	I:C3163918
thrombus	I:C3163918
)	O
in	O
patients	O
with	O
preserved	O
hepatic	O
function	I:C0232741
,	O
and	O
to	O
address	O
the	O
efficacy	O
of	O
additional	O
chemoinfusion	O
after	O
transarterial	O
chemoembolization	I:C3539919
(	O
transarterial	O
chemoembolization	I:C3539919
+	O
CI	B:C0574032
)	O
.	O

From	O
January	O
2003	O
to	O
December	O
2012	O
,	O
transarterial	B:C3539919
chemoembolization	I:C3539919
was	O
conducted	O
on	O
81	O
patients	O
with	O
Child	O
-	I:C2347612
Pugh	I:C2347612
score	I:C2347612
≤	O
7	O
who	O
had	O
hepatocellular	O
carcinoma	I:C2239176
with	O
subsegmental	O
portal	I:C3163918
vein	I:C3163918
tumour	I:C3163918
thrombus	I:C3163918
.	O

From	O
January	O
2003	O
to	O
December	O
2012	O
,	O
transarterial	O
chemoembolization	I:C3539919
was	O
conducted	O
on	O
81	O
patients	O
with	O
Child	B:C2347612
-	I:C2347612
Pugh	I:C2347612
score	I:C2347612
≤	O
7	O
who	O
had	O
hepatocellular	O
carcinoma	I:C2239176
with	O
subsegmental	O
portal	I:C3163918
vein	I:C3163918
tumour	I:C3163918
thrombus	I:C3163918
.	O

From	O
January	O
2003	O
to	O
December	O
2012	O
,	O
transarterial	O
chemoembolization	I:C3539919
was	O
conducted	O
on	O
81	O
patients	O
with	O
Child	O
-	I:C2347612
Pugh	I:C2347612
score	I:C2347612
≤	O
7	O
who	O
had	O
hepatocellular	B:C2239176
carcinoma	I:C2239176
with	O
subsegmental	O
portal	I:C3163918
vein	I:C3163918
tumour	I:C3163918
thrombus	I:C3163918
.	O

From	O
January	O
2003	O
to	O
December	O
2012	O
,	O
transarterial	O
chemoembolization	I:C3539919
was	O
conducted	O
on	O
81	O
patients	O
with	O
Child	O
-	I:C2347612
Pugh	I:C2347612
score	I:C2347612
≤	O
7	O
who	O
had	O
hepatocellular	O
carcinoma	I:C2239176
with	O
subsegmental	B:C3163918
portal	I:C3163918
vein	I:C3163918
tumour	I:C3163918
thrombus	I:C3163918
.	O

Thirty	O
-	O
one	O
of	O
them	O
underwent	O
transarterial	B:C3539919
chemoembolization	I:C3539919
+	O
CI	O
.	O

Thirty	O
-	O
one	O
of	O
them	O
underwent	O
transarterial	O
chemoembolization	I:C3539919
+	O
CI	B:C0574032
.	O

The	O
overall	O
survival	O
(	O
OS	O
)	O
and	O
serious	B:C1519255
adverse	I:C1519255
events	I:C1519255
(	O
serious	O
adverse	I:C1519255
events	I:C1519255
)	O
were	O
evaluated	O
.	O

The	O
overall	O
survival	O
(	O
OS	O
)	O
and	O
serious	O
adverse	I:C1519255
events	I:C1519255
(	O
serious	B:C1519255
adverse	I:C1519255
events	I:C1519255
)	O
were	O
evaluated	O
.	O

The	O
efficacy	O
of	O
transarterial	B:C3539919
chemoembolization	I:C3539919
+	O

CI	B:C0574032
was	O
appraised	O
after	O
adjustment	O
with	O
inverse	O
probability	O
of	O
treatment	O
weighting	O
(	O
IPTW	O
)	O
.	O

The	O
OS	O
after	O
transarterial	B:C3539919
chemoembolization	I:C3539919
(	O
median	O
,	O
15.5	O
months	O
)	O
was	O
significantly	O
related	O
with	O
aspartate	O
aminotransferase	I:C0004002
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
,	O
1.011	O
)	O
,	O
modified	O
Barcelona	O
Clinic	I:C3899975
Liver	I:C3899975
Cancer	I:C3899975
(	I:C3899975
BCLC	I:C3899975
)	I:C3899975
stage	I:C3899975
D	I:C3899975
(	O
HR	O
,	O
2.841	O
)	O
,	O
extrahepatic	O
spread	O
(	O
HR	O
,	O
4.862	O
)	O
,	O
and	O
transarterial	O
chemoembolization	I:C3539919
+	O
CI	O
(	O
HR	O
,	O
.367	O
)	O
.	O

The	O
OS	O
after	O
transarterial	O
chemoembolization	I:C3539919
(	O
median	O
,	O
15.5	O
months	O
)	O
was	O
significantly	O
related	O
with	O
aspartate	B:C0004002
aminotransferase	I:C0004002
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
,	O
1.011	O
)	O
,	O
modified	O
Barcelona	O
Clinic	I:C3899975
Liver	I:C3899975
Cancer	I:C3899975
(	I:C3899975
BCLC	I:C3899975
)	I:C3899975
stage	I:C3899975
D	I:C3899975
(	O
HR	O
,	O
2.841	O
)	O
,	O
extrahepatic	O
spread	O
(	O
HR	O
,	O
4.862	O
)	O
,	O
and	O
transarterial	O
chemoembolization	I:C3539919
+	O
CI	O
(	O
HR	O
,	O
.367	O
)	O
.	O

The	O
OS	O
after	O
transarterial	O
chemoembolization	I:C3539919
(	O
median	O
,	O
15.5	O
months	O
)	O
was	O
significantly	O
related	O
with	O
aspartate	O
aminotransferase	I:C0004002
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
,	O
1.011	O
)	O
,	O
modified	O
Barcelona	B:C3899975
Clinic	I:C3899975
Liver	I:C3899975
Cancer	I:C3899975
(	I:C3899975
BCLC	I:C3899975
)	I:C3899975
stage	I:C3899975
D	I:C3899975
(	O
HR	O
,	O
2.841	O
)	O
,	O
extrahepatic	O
spread	O
(	O
HR	O
,	O
4.862	O
)	O
,	O
and	O
transarterial	O
chemoembolization	I:C3539919
+	O
CI	O
(	O
HR	O
,	O
.367	O
)	O
.	O

The	O
OS	O
after	O
transarterial	O
chemoembolization	I:C3539919
(	O
median	O
,	O
15.5	O
months	O
)	O
was	O
significantly	O
related	O
with	O
aspartate	O
aminotransferase	I:C0004002
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
,	O
1.011	O
)	O
,	O
modified	O
Barcelona	O
Clinic	I:C3899975
Liver	I:C3899975
Cancer	I:C3899975
(	I:C3899975
BCLC	I:C3899975
)	I:C3899975
stage	I:C3899975
D	I:C3899975
(	O
HR	O
,	O
2.841	O
)	O
,	O
extrahepatic	B:C1517058
spread	O
(	O
HR	O
,	O
4.862	O
)	O
,	O
and	O
transarterial	O
chemoembolization	I:C3539919
+	O
CI	O
(	O
HR	O
,	O
.367	O
)	O
.	O

The	O
OS	O
after	O
transarterial	O
chemoembolization	I:C3539919
(	O
median	O
,	O
15.5	O
months	O
)	O
was	O
significantly	O
related	O
with	O
aspartate	O
aminotransferase	I:C0004002
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
,	O
1.011	O
)	O
,	O
modified	O
Barcelona	O
Clinic	I:C3899975
Liver	I:C3899975
Cancer	I:C3899975
(	I:C3899975
BCLC	I:C3899975
)	I:C3899975
stage	I:C3899975
D	I:C3899975
(	O
HR	O
,	O
2.841	O
)	O
,	O
extrahepatic	O
spread	O
(	O
HR	O
,	O
4.862	O
)	O
,	O
and	O
transarterial	B:C3539919
chemoembolization	I:C3539919
+	O
CI	O
(	O
HR	O
,	O
.367	O
)	O
.	O

The	O
OS	O
after	O
transarterial	O
chemoembolization	I:C3539919
(	O
median	O
,	O
15.5	O
months	O
)	O
was	O
significantly	O
related	O
with	O
aspartate	O
aminotransferase	I:C0004002
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
,	O
1.011	O
)	O
,	O
modified	O
Barcelona	O
Clinic	I:C3899975
Liver	I:C3899975
Cancer	I:C3899975
(	I:C3899975
BCLC	I:C3899975
)	I:C3899975
stage	I:C3899975
D	I:C3899975
(	O
HR	O
,	O
2.841	O
)	O
,	O
extrahepatic	O
spread	O
(	O
HR	O
,	O
4.862	O
)	O
,	O
and	O
transarterial	O
chemoembolization	I:C3539919
+	O
CI	B:C0574032
(	O
HR	O
,	O
.367	O
)	O
.	O

The	O
SAE	B:C1519255
incidence	O
was	O
significantly	O
associated	O
with	O
modified	O
BCLC	O
stages	I:C3899974
(	O
HR	O
,	O
10.174	O
[	O
proper	O
-	O
C	O
]	O
and	O
24.000	O
[	O
D	O
]	O
)	O
.	O

The	O
SAE	O
incidence	O
was	O
significantly	O
associated	O
with	O
modified	O
BCLC	B:C3899974
stages	I:C3899974
(	O
HR	O
,	O
10.174	O
[	O
proper	O
-	O
C	O
]	O
and	O
24.000	O
[	O
D	O
]	O
)	O
.	O

After	O
IPTW	O
adjustment	O
,	O
transarterial	B:C3539919
chemoembolization	I:C3539919
+	O
CI	O
significantly	O
improved	O
OS	O
(	O
p	O
=	O
.028	O
;	O
HR	O
,	O
.511	O
)	O
,	O
but	O
the	O
SAE	O
incidence	O
was	O
not	O
significantly	O
altered	O
(	O
p	O
=	O
.737	O
;	O
HR	O
,	O
.819	O
)	O
.	O

After	O
IPTW	O
adjustment	O
,	O
transarterial	O
chemoembolization	I:C3539919
+	O
CI	B:C0574032
significantly	O
improved	O
OS	O
(	O
p	O
=	O
.028	O
;	O
HR	O
,	O
.511	O
)	O
,	O
but	O
the	O
SAE	O
incidence	O
was	O
not	O
significantly	O
altered	O
(	O
p	O
=	O
.737	O
;	O
HR	O
,	O
.819	O
)	O
.	O

After	O
IPTW	O
adjustment	O
,	O
transarterial	O
chemoembolization	I:C3539919
+	O
CI	O
significantly	O
improved	O
OS	O
(	O
p	O
=	O
.028	O
;	O
HR	O
,	O
.511	O
)	O
,	O
but	O
the	O
SAE	B:C1519255
incidence	O
was	O
not	O
significantly	O
altered	O
(	O
p	O
=	O
.737	O
;	O
HR	O
,	O
.819	O
)	O
.	O

transarterial	B:C3539919
chemoembolization	I:C3539919
can	O
be	O
an	O
effective	O
and	O
safe	O
treatment	O
option	O
for	O
hepatocellular	O
carcinoma	I:C2239176
with	O
subsegmental	O
portal	I:C3163918
vein	I:C3163918
tumour	I:C3163918
thrombus	I:C3163918
in	O
patients	O
with	O
preserved	O
hepatic	O
function	I:C0232741
.	O

transarterial	O
chemoembolization	I:C3539919
can	O
be	O
an	O
effective	O
and	O
safe	O
treatment	B:C0087111
option	O
for	O
hepatocellular	O
carcinoma	I:C2239176
with	O
subsegmental	O
portal	I:C3163918
vein	I:C3163918
tumour	I:C3163918
thrombus	I:C3163918
in	O
patients	O
with	O
preserved	O
hepatic	O
function	I:C0232741
.	O

transarterial	O
chemoembolization	I:C3539919
can	O
be	O
an	O
effective	O
and	O
safe	O
treatment	O
option	O
for	O
hepatocellular	B:C2239176
carcinoma	I:C2239176
with	O
subsegmental	O
portal	I:C3163918
vein	I:C3163918
tumour	I:C3163918
thrombus	I:C3163918
in	O
patients	O
with	O
preserved	O
hepatic	O
function	I:C0232741
.	O

transarterial	O
chemoembolization	I:C3539919
can	O
be	O
an	O
effective	O
and	O
safe	O
treatment	O
option	O
for	O
hepatocellular	O
carcinoma	I:C2239176
with	O
subsegmental	B:C3163918
portal	I:C3163918
vein	I:C3163918
tumour	I:C3163918
thrombus	I:C3163918
in	O
patients	O
with	O
preserved	O
hepatic	O
function	I:C0232741
.	O

transarterial	O
chemoembolization	I:C3539919
can	O
be	O
an	O
effective	O
and	O
safe	O
treatment	O
option	O
for	O
hepatocellular	O
carcinoma	I:C2239176
with	O
subsegmental	O
portal	I:C3163918
vein	I:C3163918
tumour	I:C3163918
thrombus	I:C3163918
in	O
patients	O
with	O
preserved	O
hepatic	B:C0232741
function	I:C0232741
.	O

Furthermore	O
,	O
additional	O
chemoinfusion	B:C0574032
can	O
enhance	O
the	O
therapeutic	O
efficacy	O
while	O
maintaining	O
the	O
safety	O
.	O

•	O
transarterial	B:C3539919
chemoembolization	I:C3539919
is	O
effective	O
and	O
safe	O
for	O
treating	O
hepatocellular	O
carcinoma	I:C2239176
with	O
subsegmental	O
portal	I:C3163918
vein	I:C3163918
tumour	I:C3163918
thrombus	I:C3163918
.	O

•	O
transarterial	O
chemoembolization	I:C3539919
is	O
effective	O
and	O
safe	O
for	O
treating	O
hepatocellular	B:C2239176
carcinoma	I:C2239176
with	O
subsegmental	O
portal	I:C3163918
vein	I:C3163918
tumour	I:C3163918
thrombus	I:C3163918
.	O

•	O
transarterial	O
chemoembolization	I:C3539919
is	O
effective	O
and	O
safe	O
for	O
treating	O
hepatocellular	O
carcinoma	I:C2239176
with	O
subsegmental	B:C3163918
portal	I:C3163918
vein	I:C3163918
tumour	I:C3163918
thrombus	I:C3163918
.	O

•	O
Modified	O
BCLC	B:C3899974
stages	I:C3899974
can	O
stratify	O
the	O
risk	O
and	O
benefit	O
of	O
transarterial	O
chemoembolization	I:C3539919
.	O

•	O
Modified	O
BCLC	O
stages	I:C3899974
can	O
stratify	O
the	O
risk	B:C0086930
and	O
benefit	O
of	O
transarterial	O
chemoembolization	I:C3539919
.	O

•	O
Modified	O
BCLC	O
stages	I:C3899974
can	O
stratify	O
the	O
risk	O
and	O
benefit	O
of	O
transarterial	B:C3539919
chemoembolization	I:C3539919
.	O

•	O
Additional	O
chemoinfusion	B:C0574032
can	O
enhance	O
the	O
therapeutic	O
efficacy	O
while	O
maintaining	O
the	O
safety	O
.	O

